On March 24, 2026, Oncotelic Therapeutics, Inc. announced that its subsidiary, Sapu Nano, will introduce its Deciparticle™ nanomedicine platform at the upcoming Bio-Europe Spring 2026 event. This platform is designed to enhance drug delivery and optimize therapeutic outcomes in oncology. The presentation is scheduled for March 25, 2026, at Theater A during the conference. Sapu Nano aims to unveil two lead clinical candidates: Sapu003, an intravenous formulation of Everolimus, and Sapu006, an advanced formulation of Docetaxel. Both candidates are currently in Phase 1 clinical trials, with the potential to significantly improve treatment efficacy and safety compared to conventional formulations. The Deciparticle™ platform represents a significant advancement in drug delivery technology, focusing on optimizing tissue distribution and enhancing therapeutic index. This development is expected to attract interest from potential partners and investors, positioning Oncotelic for future growth in the competitive biopharmaceutical landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.